The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biomarker study evaluating the combination of dabrafenib (D) with trametinib (T) versus the combination after 8 weeks of monotherapy with dabrafenib or trametinib in patients with metastatic and unresectable stage IIIC or IV melanoma: GSK study 116613.
Christine Mateus
No relevant relationships to disclose
Emilie Routier
No relevant relationships to disclose
Severine Roy
No relevant relationships to disclose
Marina Thomas
No relevant relationships to disclose
Lise Boussemart
No relevant relationships to disclose
Isabelle Girault
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Nathalie Chaput-Gras
No relevant relationships to disclose
Stephan Vagner
No relevant relationships to disclose
Hugo Cazenave
No relevant relationships to disclose
Lindi D Dalland
Employment or Leadership Position - GlaxoSmithKline
Mike R Lau
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Maureen R Bleam
Employment or Leadership Position - GlaxoSmithKline
Anthony Michael D'amelio
Employment or Leadership Position - GlaxoSmithKline
Sylvie Pfersch
Employment or Leadership Position - GlaxoSmithKline
Caroline Caty
Employment or Leadership Position - GlaxoSmithKline
Caroline Robert
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche